Objectives: To assess the effect of sodium valproate, levetiracetam, and lamotrigine on seizure attacks and EEG disorders in patients with juvenile myoclonic epilepsy.
Design: a double blind randomized clinical trial.
Setting and conduct: The eligible patients with juvenile myoclonic epilepsy who will refer to Imam Khomeini Clinic during the study period will be enrolled into the trial.
Inclusion criteria: affected with juvenile myoclonic epilepsy; age of over 12 years.
Exclusion criteria: having severe organic diseases, heart failure, liver disorder, renal disease, or electrolyte disorder; abnormal MRI image; mental retardation; pregnancy or breastfeeding; alcohol or drug dependence; needing to more than one drug for controlling seizure; noncompliance.
Intervention group 1: oral levetiracetam 500 mg twice a day for 6 months.
Intervention group 2: oral lamotrigine 100 mg twice a day for 6 months.
Control group: Oral sodium valproate 500 mg once a day for 6 months.
Primary outcome: Assessing seizure attacks before intervention, and 1, 2, and 6 months after intervention through history taking.
Secondary outcome: Assessing EEG disorders before intervention, and 1, 2, and 6 months after intervention using electroencephalogram.
Randomization: Random assignment of the patients to the intervention and control groups one at a time.
Blinding: Patients will be unaware of the type of intervention. The physician who will examine the patients will not be aware of the intervention. Therefore, the trial will be run as double blind.